| Chemical Properties | Back Directory | [density ]
1.281±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [solubility ]
DMSO: Soluble: =10 mg/ml | [form ]
Solid | [pka]
-4.475±0.53(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research[1]. | [in vivo]
FDW028 (10 or 20 mg/kg, i.v. every other day) exhibits significant anti-tumor activity in the SW480 xenograft mouse model[1].
FDW028 (20 mg/kg, i.v. every other day) significantly prolongs survival in the Mc38 pulmonary metastasis model[1]. | Animal Model: | Colorectal cancer cell line SW480 xenograft mouse model (C57BL/6 mice, 4-6 weeks)[1] | | Dosage: | 10 mg/kg, 20 mg/kg | | Administration: | Intravenous injection (i.v.), every other day, tumor size and body weight were measured every other day during the experiment | | Result: | Inhibited tumor growth, comparable to 5-Fu (HY-90006), and did not cause significant weight loss. |
| Animal Model: | Mc38 colorectal cancer pulmonary metastasis mouse model (C57BL/6 mice, 4-6 weeks)[1] | | Dosage: | 20 mg/kg | | Administration: | Intravenous injection (i.v.), every other day, were measured every other day during the experiment | | Result: | Significantly prolonged the survival of tumor-bearing mice. |
| [References]
[1] Wang M, et al. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. Cell Death Dis. 2023 Aug 3;14(8):495. DOI:10.1038/s41419-023-06027-0 |
|
|